Aquestive Therapeutics AQST 深 滬
等待開盤 08-06 09:30:00 美东时间
3.94
-0.080
-1.99%
華盛通- 最 高4.065
- 今 開4.02
- 成交量 71.24万股
- 最 低 3.875
- 昨 收 4.02
- 總市值 3.91亿
- 52周最高 5.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.12
- 委 比 -11.43%
- 總股本 9932.79万
- 歷史最高 20.696
- 量 比 0.97
- 振 幅 4.73%
- 歷史最低 0.618
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics will report Q2 2025 results and update on business developments after market close on August 11, 2025. A conference call for investors will be held at 8:00 a.m. ET on August 12, 2025. Registration is required to access the call and obtain a personal pin. A live webcast will be available on Aquestive’s website, with a replay archived for 30 days. The company, focusing on innovative medicines, has four commercialized products...
08-04 11:00
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
Aquestive Therapeutics promoted Sherry Korczynski to Chief Commercial Officer effective July 22, 2025, recognizing her expertise in allergy therapeutics and leadership in commercial operations. Korczynski, who joined Aquestive in 2024, will oversee the global launch of Anaphylm™, an innovative orally delivered epinephrine product designed for anaphylaxis care. The company emphasizes Anaphylm's potential as the first device-free, orally administer...
07-22 11:00
Aquestive Seeks Approval for Needle-Free Allergy Film in Canada and Europe, Eyes Global Expansion
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
07-15 19:05
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics announced plans for a meeting with Health Canada in the third quarter of 2025 to discuss their New Drug Submission for Anaphylm™ (epinephrine) Sublingual Film and submitted an initial briefing book to the European Medicines Agency. CEO Dan Barber emphasized these steps as key to their ex-U.S. regulatory strategy, aiming to bring needle-free Anaphylm to underserved patients globally. Anaphylm, designed to be orally administe...
07-15 11:00
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics announced that its management team will participate in the Leerink Partners Therapeutics Forum on July 9, 2025, focusing on immunology, inflammation, and metabolism. The company, which develops innovative oral and topical treatments, is advancing a severe allergic reaction therapy and a topical gel for dermatological conditions. The event will also include one-on-one investor meetings.
07-07 11:00
Aquestive Highlights Oral Epinephrine Film for Severe Allergies at Upcoming Chicago Summit
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
06-25 19:01
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
Aquestive Therapeutics will present two posters on Anaphylm™ at the CFAAR Food Allergy Summit, highlighting its stability under extreme conditions and rapid pharmacokinetic responses. Anaphylm is an orally administered epinephrine film aimed to treat severe allergic reactions and anaphylaxis. If approved by the FDA, it would be the first oral epinephrine option in the U.S. The company emphasizes its convenience, portability, and weather-resistanc...
06-25 11:00
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Aquestive gains as allergy therapy undergoes FDA review
Aquestive Therapeutics (NASDAQ:AQST) added ~5% in the premarket on Monday after the biopharma announced that the FDA accepted its New Drug Application for allergy therapy Anaphylm for review. With the...
06-16 20:23
The FDA Has Accepts Aquestive Therapeutics' New Drug Application For Anaphylm For Type 1 Allergic Reactions, Including Anaphylaxis, With PDUFA Target Action Date Of January 31, 2026
If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
06-16 19:04
